H. Zimdahl‐Gelling

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

Jing Yuan, Hans Guenter Schaefer, Thorsten Lehr, 2011, Pharmacogenetics and genomics.

A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers

M. Sand, F. Runge, Viktoria Moschetti, 2017, Human psychopharmacology.

Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding

S. Yusuf, M. Ezekowitz, S. Connolly, 2013, Circulation.

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

F Müller, F. Müller, K. Hohl, 2016, Clinical pharmacology and therapeutics.

First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males

M. Sand, Viktoria Moschetti, H. Zimdahl‐Gelling, 2016, British journal of clinical pharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-rising doses of bi409306 film-coated tablets given orally once- or twice-daily for 14 days in young and elderly healthy volunteers

M. Sand, A. Borta, Viktoria Moschetti, 2015, Alzheimer's & Dementia.